← Back to Clinical Trials
Recruiting NCT04538859

NCT04538859 A Prospective Study of Factors Related to Exacerbation and Mortality of Non-cystic Fibrosis Bronchiectasis in Hong Kong

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04538859
Status Recruiting
Phase
Sponsor Chinese University of Hong Kong
Condition Bronchiectasis Adult
Study Type OBSERVATIONAL
Enrollment 400 participants
Start Date 2020-08-30
Primary Completion 2027-08-29

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 400 participants in total. It began in 2020-08-30 with a primary completion date of 2027-08-29.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Bronchiectasis is associated with repeated exacerbations which occurs at rates of 1.5-6.5 per patients per year, and are associated with an increased risk of admission and readmission to hospital, and high health care costs. In a local study carried out more than 10 years ago, idiopathic disease dominates and patients with bronchiectasis are mainly female with high hospitalization and mortality rates; 21.9 cases per 100,000 and 2.7 cases per 100,000 respectively. Moreover, exacerbation characterized by increases in symptoms requiring antibiotic treatment is associated with disease progression and significant mortality. Updated prevalence of this disease with the characteristics of etiology, clinical presentation and outcomes are needed to guide further management plan.

Eligibility Criteria

Inclusion Criteria: 1. Patients aged 18 years or older 2. Clinically stable for at least 4 weeks prior to enrollment (defined as no symptoms of exacerbation, no requirement for supplemental antibiotic therapy) 3. Diagnosis of bronchiectasis defined by high-resolution computed tomography scan Exclusion Criteria: 1. History of cystic fibrosis; hypogammaglobulinemia; allergic bronchopulmonary aspergilosis 2. Those who are unable to give consent

Frequently Asked Questions

Who can join the NCT04538859 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Bronchiectasis Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04538859 currently recruiting?

Yes, NCT04538859 is actively recruiting participants. Visit ClinicalTrials.gov or contact Chinese University of Hong Kong to inquire about joining.

Where is the NCT04538859 trial being conducted?

This trial is being conducted at Hong Kong, Hong Kong.

Who is sponsoring the NCT04538859 clinical trial?

NCT04538859 is sponsored by Chinese University of Hong Kong. The trial plans to enroll 400 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology